TAC1 and kidney cancer: In addition to inflammatory disorders as noted previously, loss of NKA activity has been found to be associated with tumour invasiveness, metastasis, and tissue fibrosis [54], kidney cancer [54], prostate cancer [55], bladder cancer [56] and urothelial cancer [57].